Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Reducing Existing Costs Associated with Pharmaceuticals for Seniors Act of 2017 or the RxCAP Act of 2017 This bill amends title XVIII (Medicare) of the Social Security Act to eliminate beneficiary cost-sharing above the Medicare prescription benefit's annual out-of-pocket threshold beginning in plan year 2018. Under current law, the Medicare prescription drug benefit provides coverage above that threshold only with cost-sharing in the form of either copayment or coinsurance.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · fourth_quarter · Health Issues
Cancer Drug Parity Act (HR 1409); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); HHS guidance on ACA section 1332 waivers; pediatric cancer research
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Health Issues
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Client expense: $60,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Medicare/Medicaid
Part B Part D Medicaid S. 1347, RxCAP Act S. 2553, Know the Lowest Price Act
Client expense: $75,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
2018 · second_quarter · Health Issues
Cancer Drug Parity Act (HR 1409); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); the FAIR Care Act (S 2494); Patient Advocacy Transparency Act (S. 3000); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Health Issues
S. 2852, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; H.R. 4710, 340B PAUSE Act; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; S. 204, H.R. 878, Trickett Wendler Right to Try Act of 2017; H.R. 5247, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018; H.R. 2077, Restoring the Patient's Voice Act of 2017; H.R. 1409, Cancer Drug Parity Act; S. 637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; S. 1681, A bill to require persons who undertake Federally funded research and development of drugs to enter into reasonable pricing agreements with the Secretary of Health and Human Services; Proposals related to drug pricing; S. 1347, RxCAP Act of 2017; 42 USC 1320a-7b, Anti-Kickback Statute; H.R. 5867, H.R. 6142, Reducing Drug Waste Act of 2018; Discussions related to mental health/depression in the opioid epidemic;
Client expense: $840,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · second_quarter · Pharmacy
S 2011/HR 4138-Medicare Drug Price Negotiation Act, S 974/HR 2212-CREATES Act of 2017, S 124-Preserve Access to Affordable Generics Act, HR 1625-OMNIBUS, opioid addiction data analysis, S 771-Improving access to affordable prescription drugs act, S 252-Medicare Drug Savings act of 2017, S 1369-Stop Price Gouging Act, S 495-Medical innovation and prize fund act, S 1131/HR 2439-FAIR drug pricing act, HR 4117-Competitive Drugs act of 2017, S 771/HR 1776-Improving access to affordable prescription drugs act, S 637-C-THRU Act, S 1347-RxCap Act of 2017, S 1348-SPIKE Act of 2017, HR 5156-Protecting Medicare from Excessive Price Increases Act of 2018, S 2691-Opioid Crisis accountability act of 2018, S 2315-Over the counter drug safety, innovation, and reform act, S 2700/HR 5545-Comprehensive Addiction Resources Emergency (CARE) act, Drug Pricing-Medicare Part D HR 2051-FAST Generics Act of 2017, HR 4116-Transparent Drug Pricing Act, S 2852-Pandemic and All-Hazards Preparedness Act and advancing innovative Act of 2018,
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Securities & Exchange Commission (SEC), U.S. Trade Representative (USTR)
2018 · first_quarter · Medicare/Medicaid
Part B Part D Medicaid S. 1347, RxCAP Act
Client expense: $200,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Veterans Affairs, Dept of (VA)
2018 · first_quarter · Health Issues
Cancer Drug Parity Act (HR 1409, Senate bill not yet introduced); the Right to Try Act (S 204, HR 878); the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (HR 5247); Patients' Access to Treatments Act of 2017 (HR 2999); Childhood Cancer STAR Act (HR 820/S 292); RxCAP Act of 2017 (S 1347); insurance plan benefit design related to high-cost prescription drugs; Affordable Care Act market stabilization negotiations; pediatric cancer research
Client expense: $75,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
| Democratic |
| CO |
| Sheldon Whitehouse | Democratic | RI |